Patents by Inventor Christine C. Siska

Christine C. Siska has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody therapies for human immunodeficiency virus (HIV)
    Patent number: 11845788
    Abstract: Featured are PGT121 variant antibodies or fragments thereof, which can be administered, e.g., as antibody therapies for treating human immunodeficiency virus (HIV) infection. In particular, featured are methods of treating subjects infected with HIV and/or blocking HIV infections in subjects at risk of HIV transmission using the PGT121 variant antibodies or fragments thereof.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: December 19, 2023
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Dan H. Barouch, Bruce A. Kerwin, Randal R. Ketchem, Alison J. Gillespie, Christine C. Siska, Rutilio H. Clark, Julee A. Floyd, Jeremy M. Shaver, Richard S. Rogers
  • Anti-HIV Antibody 10-1074 Variants
    Publication number: 20220119504
    Abstract: The present disclosure provides optimized broadly-neutralizing anti-HIV antibodies, having modified light chain variable regions and/or heavy chain variable regions leading to improved biophysical characteristics. The present disclosure also provides methods for producing these anti-HIV antibodies and methods of use thereof.
    Type: Application
    Filed: September 12, 2019
    Publication date: April 21, 2022
    Inventors: Michel Nussenzweig, Randal R. Ketchem, Christine C. Siska, Alison J. Gillespie, Rutilio H. Clark, Bruce A. Kerwin
  • ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV)
    Publication number: 20220025021
    Abstract: Featured are PGDM1400 variant antibodies or fragments thereof, which can be administered, e.g., as antibody therapies for treating human immunodeficiency virus (HIV) infection. In particular, featured are methods of treating or curing subjects infected with HIV and/or preventing HIV infections in subjects at risk of HIV transmission using the PGDM1400 variant antibodies or fragments thereof.
    Type: Application
    Filed: November 19, 2019
    Publication date: January 27, 2022
    Inventors: Dan H. BAROUCH, Bruce A. KERWIN, Randal R. KETCHEM, Alison J. GILLESPIE, Christine C. SISKA, Rutilio H. CLARK, Julee A. FLOYD, Jeremy M. SHAVER
  • AFLIBERCEPT FORMULATIONS AND USES THEREOF
    Publication number: 20220016210
    Abstract: Ophthalmic formulations comprising aflibercept are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.
    Type: Application
    Filed: October 3, 2021
    Publication date: January 20, 2022
    Applicant: Just-Evotec Biologics, Inc.
    Inventors: Bruce A. Kerwin, Julee A. Floyd, Alison J. Gillespie, Christine C. Siska
  • Aflibercept formulations and uses thereof
    Patent number: 11135266
    Abstract: Ophthalmic formulations comprising aflibercept are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: October 5, 2021
    Assignee: Just-Evotec Biologics, Inc.
    Inventors: Bruce A. Kerwin, Julee A. Floyd, Alison J. Gillespie, Christine C. Siska
  • ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV)
    Publication number: 20210206838
    Abstract: Featured are PGT121 variant antibodies or fragments thereof, which can be administered, e.g., as antibody therapies for treating human immunodeficiency virus (HIV) infection. In particular, featured are methods of treating subjects infected with HIV and/or blocking HIV infections in subjects at risk of HIV transmission using the PGT121 variant antibodies or fragments thereof.
    Type: Application
    Filed: May 22, 2019
    Publication date: July 8, 2021
    Inventors: Dan H. BAROUCH, Bruce A. KERWIN, Randal R. KETCHEM, Alison J. GILLESPIE, Christine C. SISKA, Rutilio H. CLARK, Julee A. FLOYD, Jeremy M. SHAVER, Richard S. ROGERS
  • AFLIBERCEPT FORMULATIONS CONTAINING A LYSINE SALT AS TONICIFYING AGENT AND USES THEREOF
    Publication number: 20210170029
    Abstract: Ophthalmic formulations comprising aflibercept and a lysine salt tonicifying agent are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.
    Type: Application
    Filed: November 18, 2018
    Publication date: June 10, 2021
    Applicant: Just-Evotec Biologies, Inc.
    Inventors: Alison J. Gillespie, Julee A. Floyd, Bruce A. Kerwin, Christine C. Siska
  • AFLIBERCEPT FORMULATIONS AND USES THEREOF
    Publication number: 20190298801
    Abstract: Ophthalmic formulations comprising aflibercept are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.
    Type: Application
    Filed: November 20, 2017
    Publication date: October 3, 2019
    Applicant: Just Biotherapeutics, Inc.
    Inventors: Bruce A. Kerwin, Julee A. Floyd, Alison J. Gillespie, Christine C. Siska